Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma

被引：2

作者：

Portuguese, Andrew J. ^{[1
,2
,6
]}

Fang, Min ^{[1
,2
]}

Tuazon, Sherilyn A. ^{[1
,3
]}

Pont, Margot ^{[1
,4
]}

Qu, Xiaoyu ^{[1
,2
]}

Shasha, Carolyn ^{[1
]}

Comstock, Melissa ^{[1
]}

Lyons, Justina ^{[1
]}

Cole, Gabriel ^{[1
,4
]}

Newell, Evan W. ^{[1
,2
]}

Glynn, Emily ^{[2
]}

Soma, Lorinda A. ^{[1
,5
]}

Green, Damian J. ^{[1
,2
]}

机构：

[1] Fred Hutchinson Canc Ctr, Clin Res Div, Seattle, WA USA

[2] Univ Washington, Dept Med, Seattle, WA USA

[3] Bristol Myers Squibb, Seattle, WA USA

[4] Galapagos Co, CellPoint Bio, Oegstgeest, Netherlands

[5] City Hope Med Ctr, Dept Pathol, Duarte, CA USA

[6] Fred Hutchinson Canc Ctr, 1100 Fairview Ave N, M2-B230, Seattle, WA 98109 USA

来源：

BLOOD ADVANCES | 2023年 / 7卷 / 23期

关键词：

INTERFERES; EXPRESSION; CELLS;

D O I：

10.1182/bloodadvances.2023011295

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：7235 / 7238

页数：4

共 13 条

[1] Bataille R, 2006, HAEMATOLOGICA, V91, P1234
[2] Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping
Chami, Btissam
Okuda, Makoto
Moayeri, Morvarid
Pirenne, France
Hidaka, Yoko
Nambiar, Ashok
Song, Zhili
Bedel, Olivier
Zhang, Bailin
Hopke, Joern
Deng, Gejing
Zhu, Chen
Mace, Sandrine
Chiron, Marielle
Adrian, Francisco
Fukao, Taro
Basile, Frank G.
Martin, Thomas
[J]. TRANSFUSION, 2022, 62 (11) : 2334 - 2348
[3] Courville EL, 2020, AM J CLIN PATHOL, V153, P221, DOI [10.1093/AJCP/AQZ153, 10.1093/ajcp/aqz153]
[4] Darzalex (daratumumab), 2022, Package insert
[5] Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
de Weers, Michel
Tai, Yu-Tzu
van der Veer, Michael S.
Bakker, Joost M.
Vink, Tom
Jacobs, Danielle C. H.
Oomen, Lukas A.
Peipp, Matthias
Valerius, Thomas
Slootstra, Jerry W.
Mutis, Tuna
Bleeker, Wim K.
Anderson, Kenneth C.
Lokhorst, Henk M.
van de Winkel, Jan G. J.
Parren, Paul W. H. I.
[J]. JOURNAL OF IMMUNOLOGY, 2011, 186 (03) : 1840 - 1848
[6] Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Gandhi, Ujjawal H.
Cornell, Robert F.
Lakshman, Arjun
Gahvari, Zhubin J.
McGehee, Elizabeth
Jagosky, Megan H.
Gupta, Ridhi
Varnado, William
Fiala, Mark A.
Chhabra, Saurabh
Malek, Ehsan
Mansour, Joshua
Paul, Barry
Barnstead, Alyssa
Kodali, Saranya
Neppalli, Amarendra
Liedtke, Michaela
Narayana, Swapna
Godby, Kelly N.
Kang, Yubin
Kansagra, Ankit
Umyarova, Elvira
Scott, Emma C.
Hari, Parameswaran
Vij, Ravi
Usmani, Saad Z.
Callander, Natalie S.
Kumar, Shaji K.
Costa, Luciano J.
[J]. LEUKEMIA, 2019, 33 (09) : 2266 - 2275
[7] Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma
Ise, Mikiko
Matsubayashi, Keiko
Tsujimura, Hideki
Kumagai, Kyoya
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (05) : E59 - E64
[8] Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma
Lin, P
Owens, R
Tricot, G
Wilson, CS
[J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 121 (04) : 482 - 488
[9] CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy
Minarik, Jiri
Novak, Martin
Flodr, Patrik
Balcarkova, Jana
Mlynarcikova, Miroslava
Krhovska, Petra
Pika, Tomas
Pikalova, Zuzana
Bacovsky, Jaroslav
Scudla, Vlastimil
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (02) : 186 - 189
[10] Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
Nijhof, I. S.
Groen, R. W. J.
Lokhorst, H. M.
van Kessel, B.
Bloem, A. C.
van Velzen, J.
de Jong-Korlaar, R.
Yuan, H.
Noort, W. A.
Klein, S. K.
Martens, A. C. M.
Doshi, P.
Sasser, K.
Mutis, T.
van de Donk, N. W. C. J.
[J]. LEUKEMIA, 2015, 29 (10) : 2039 - 2049

← 1 2 →